Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.

Oncogene | May 3, 2012

Cell identity is determined by its gene expression programs. The ability of a cell to change its identity and produce cell types outside its lineage is achieved by the activity of transcription controllers capable of reprogramming differentiation gene networks. The synovial sarcoma (SS)-associated protein, SYT-SSX2, reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells (BMMSCs) by dictating their commitment to a pro-neural lineage. It fulfills this function by directly targeting an extensive array of neural-specific genes as well as genes of developmental pathway mediators. Concomitantly, the ability of both myoblasts and BMMSCs to differentiate into their normal myogenic and adipogenic lineages was compromised. SS is believed to arise in mesenchymal stem cells where formation of the t(X/18) translocation product, SYT-SSX, constitutes the primary event in the cancer. SYT-SSX is therefore believed to initiate tumorigenesis in its target stem cell. The data presented here allow a glimpse at the initial events that likely occur when SYT-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation. In addition, we identified the fibroblast growth factor receptor gene, Fgfr2, as one occupied and upregulated by SYT-SSX2. Knockdown of FGFR2 in both BMMSCs and SS cells abrogated their growth and attenuated their neural phenotype. These results support the notion that the SYT-SSX2 nuclear function and differentiation effects are conserved throughout sarcoma development and are required for its maintenance beyond the initial phase. They also provide the stem cell regulator, FGFR2, as a promising candidate target for future SS therapy.

Pubmed ID: 21996728 RIS Download

Mesh terms: Cell Differentiation | Cell Line | Cell Lineage | Cell Transformation, Neoplastic | Gene Knockdown Techniques | Humans | Mesenchymal Stromal Cells | Myoblasts | Neurons | Oncogene Proteins, Fusion | Receptor, Fibroblast Growth Factor, Type 2 | Sarcoma, Synovial

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NCRR NIH HHS, Id: P40RR017447
  • Agency: NEI NIH HHS, Id: P30 EY08126
  • Agency: NCI NIH HHS, Id: P30 CA68485
  • Agency: NIDDK NIH HHS, Id: P30 DK058404
  • Agency: NCRR NIH HHS, Id: P40 RR017447
  • Agency: NEI NIH HHS, Id: P30 EY008126
  • Agency: NCI NIH HHS, Id: P30 CA068485
  • Agency: NCI NIH HHS, Id: T32 CA009592
  • Agency: NIDDK NIH HHS, Id: P30 DK58404

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.